Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the company's long-term ...
Adjusted EPS of $0.92 topped estimates of $0.53. Revenue climbed to $747 million, beating the forecasted $712 million. Net ...
BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...
Scotiabank raised the firm’s price target on BioMarin (BMRN) to $80 from $78 and keeps a Sector Perform rating on the shares. The firm is raising its price target on the stock following a Q4 Voxzogo ...
BioMarin Pharmaceutical Inc. ( NASDAQ: BMRN) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO ...
UBS analyst Eliana Merle raised the firm’s price target on BioMarin (BMRN) to $113 from $109 and keeps a Buy rating on the shares. BioMarin ...
Total Revenues increased 16% year over year, driven by Voxzogo contributions from new patient starts in all regions. In the quarter, revenues from BioMarin's Enzyme Therapies increased 9% ...
周一，Oppenheimer分析师上调了BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )的股票评级，从"持平"上调至"优于大市"，并设定目标价为$98.00。此次上调是基于BioMarin在2024年第四季度的强劲表现，公司总收入达到$747 million，超过市场预期的$712 ...
周四，BMO Capital Markets维持BioMarin Pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback